Reply to “Rigor, reproducibility and in vitro CSF assays: The devil in the details”

    loading  Checking for direct PDF access through Ovid


We thank Moody et al for their reply on in vitro cerebrospinal fluid (CSF) assay from hypersomnolent patients for a type A gamma‐aminobutyric acid (GABA‐A) potentiating activity, in response to our article.1 We agree partially with their letter in saying that “divergent results and misinterpretation of non‐significant findings remain problematic in science,” and would add, not only in science, but also in clinical medicine. The authors, however, strongly criticized our experimental approaches and results. We thus would like to respond to their comments, clarify some points that seem necessary, and ultimately disagree with their criticisms.
    loading  Loading Related Articles